Peptides DB
Research-centric peptide and protocol reference hub

PE 22-28 record · updated 17h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 33 studiesJump to the evidenceCompare
What is PE 22-28 used for?

PE 22-28 is a peptide that has attracted interest for its potential roles in vascular health and metabolic conditions, particularly in the context of gestational diabetes and placental function. The peptide is derived from the sequence of the human protein, and its mechanism of action is thought to involve modulation of endothelial function and inflammatory responses, which are critical in maintaining vascular integrity and metabolic homeostasis.

How it works: Modulation of endothelial function and inflammatory responses

Primarily researched for · Metabolic & appetite

Development stage

where PE 22-28 sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Current
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 70 registered trials. It describes the research record, not a recommendation.

Identity
NamePE 22-28
Chain length—
Molecular weight773.9 Da
FormulaC35H55N11O9
Structure typeNot established
ClassMetabolic
Research levelModerate Research
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 165437303. No verified residue count for this compound.

Pharmacology
MechanismModulation of endothelial function and inflammatory responses
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.60
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 31, 2026. How this works →
Research stats
Total studies33
Human / animal / cellular24 / 2 / 4
Highest trial phasePhase 1
Years covered2010–2026
Latest study17h ago
Publication history
20102026
Research funding
158 NIH projects · $35.8M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

33 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Enhancing pectin degradation and improving nutritional accessibility in potato pulp through co-fermentation: From molecular structure to nutrient release.
FindingPectin degradation reached 29.26 ± 0.41% under optimized conditions.
Animal2026Full text read0.70
Discovery of an Isothiazolinone-Containing Antitubercular Natural Product Levesquamide.
FindingMIC of 9.65 μM against Mycobacterium tuberculosis H37Rv in microplate alamarBlue assay.
In vitro2020Full text read0.70
Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis
FindingNot reported in abstract.
Animal2026Full text read0.70
TGF-β, but not IL-4, polarized macrophages induce fibrotic responses in lung fibroblasts
FindingNot reported in abstract.
In vitro2026Full text read0.70
Long term use and replacement of near vision glasses for presbyopia, in Punjab, Pakistan: a cross-sectional survey
Finding92.0% (n=254) of respondents were still using near vision glasses.
Human2026Full text read0.80
Multimodal ctDNA profiling for cancer detection and monitoring in pan-cancer patients with advanced disease enrolled in the SHIVA02 trial
Finding93.8% ctDNA detection with the three-step integrative model.
Human2026Full text read0.80
An Online Survey of Healthcare Professionals to Understand the Use of Clinical Prediction Models in Practice
FindingMedian usefulness rating was 8 out of 10.
Human2026Full text read0.80
Exceptional methane emissions from an African papyrus wetland
Finding720.5 ± 378.7 mg CH₄ m⁻² d⁻¹
—2026Full text read0.80
Economic Burden of Oral Diseases, Barriers to Care, and Opportunities for Health System Reform in Rural Lucknow: A Mixed-Method Study
Finding81.8% clinical caries prevalence among participants.
Human2026Full text read0.90
Quality of life in children and adolescents with Tourette’s disorder: The Role of Psychiatric Comorbidities and Sex
FindingNot reported in abstract.
Human2026Full text read0.80
Association between first trimester ambient temperature and the risk of gestational hypertension and pre-eclampsia: Insights from the PRECISE study cohort in The Gambia, Kenya and Mozambique
FindingEach 1°C increase in first-trimester temperature was associated with 8% increased odds of HDP (aOR 1.08, 95%CI:1.04 to 1.13, p<0.001).
Human2026Full text read0.80
Antenatal risk stratification for preeclampsia with sFlt-1/PlGF ratio: Which is the best time to test?
FindingThe sFlt-1/PlGF ratio of 38 or more at 20-22 weeks resulted in either PE or adverse fetal outcome in all cases.
Human2023Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching PE 22-28 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much PE 22-28 is discussed should be drawn from it.